Abstract 57P
Background
Expanded use of tumour molecular testing to enable targeted treatment across multiple cancers has increased identification of potential pathogenic germline variants (pPGVs). In NSCLC, BRCA1 and BRCA2 are two potentially targetable pPGVs that are not well described despite BRCA-mutated lung cancer accounting for 1%-14% of cases. This study evaluates the frequency of BRCA1/2-mutated NSCLC identified via tumour sequencing and describes patient and tumour characteristics, family history, clinical course, and germline BRCA mutational status.
Methods
NSCLC patients who underwent tumour testing between January 1, 2018 and June 30, 2021 were identified. Next generation sequencing was used to screen for 46 tumour gene mutations including BRCA1/2, with subsequent referral for germline testing via gene specific intronic polymerase chain reaction amplification if pPGVs were identified.
Results
Of 2784 patients with NSCLC who had tumour sequencing, 44 (1.6%) had pPGVs in BRCA1/2. The majority of patients had metastatic disease at diagnosis (59.1%) and a family history of cancer in a first-degree relative (56.8%), while 34.1% had personal history of a second primary cancer. Frequently co-mutated genes were TP53 (68.2%), KRAS (40.1%), and EGFR (20.5%). Of patients who had confirmatory testing, 60% (12/20) were confirmed germline BRCA1/2 carriers. Patients with stage IV disease at time of diagnosis with germline BRCA1/2 mutation had shortened overall survival (18.7 ± 4.6 months) when compared to the 8 patients with confirmed somatic BRCA1/2 mutation (63.8 ± 21.8 months, p = 0.027).
Conclusions
BRCA1/2 tumour mutations were detected with frequency consistent with prior reports and exhibit high likelihood of associated germline mutation. The observed difference in survival of patients with advanced disease harbouring somatic versus germline mutation warrants further study and highlights the importance of confirmatory germline testing as targeted therapies emerge in order to adequately prognosticate and inform families of at-risk status.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
41P - HLA genotypes modify the age-related penetrance of BRCA1 pathogenic variants in breast cancer patients
Presenter: Ekaterina Kuligina
Session: Cocktail & Poster Display session
Resources:
Abstract
42P - Investigating the influence of extrachromosomal DNA in the progression of non-small cell lung cancer through the TRACERx and PEACE studies
Presenter: Jeanette Kittel
Session: Cocktail & Poster Display session
Resources:
Abstract
43P - MDM2 alterations in primary brain tumors: A potential niche for targeted therapy
Presenter: Diego Gomez Puerto
Session: Cocktail & Poster Display session
Resources:
Abstract
44P - Exploring miR-205 and miR-296 as salivary biomarkers and potential therapeutic targets in oral cancer
Presenter: Thaís Moré Milan
Session: Cocktail & Poster Display session
Resources:
Abstract
45P - Integrative analysis of TCGA DNA methylation, RNA-sequencing, and variant dataset using machine learning in predicting endometrial cancer recurrence
Presenter: Jinhwa Hong
Session: Cocktail & Poster Display session
Resources:
Abstract
46P - The role of microRNA-1246 in early detection of breast cancer: Findings from a systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Cocktail & Poster Display session
Resources:
Abstract
47P - Differential expression of discriminative markers in matched invasion fronts and tumour buds in CRC
Presenter: Laura Grech
Session: Cocktail & Poster Display session
Resources:
Abstract
48P - Transcriptome profiling highlights distinct gene signatures in HER2 high (HER2 3+) and HER 2 low (Her2 1+/2+) breast cancers
Presenter: Tamanna Thakur
Session: Cocktail & Poster Display session
Resources:
Abstract
49P - MiR-155 promotes breast cancer progression by upregulating cancer stemness
Presenter: Jeonghee Han
Session: Cocktail & Poster Display session
Resources:
Abstract
50P - Clinical impact of actionable molecular variants disclosed in late-stage cancer patients by tumor whole-exome sequencing in a prospective single-institution study
Presenter: Christophe Mapendano
Session: Cocktail & Poster Display session
Resources:
Abstract